Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.
ACAAI Annual Scientific Meeting - American College of Allergy, Asthma & Immunology Annual Scientific Meeting
About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Newly Approved Specialty Drugs Advance Care for Inflammatory and Autoimmune Diseases
2
Measles On the Rise: Global Surge and US Status at Risk
3
November 2025 Trending Products
4
Data Suggest Routine Multicancer Early Detection Tests Could Reduce Late–Stage Diagnoses
5
